Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  abiraterone acetate
Find trials that include:  Any drugs shown
Results 1-14 of 14 for your search:
Start Over
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Testosterone Therapy Followed by Enzalutamide or Abiraterone Acetate in Treating Patients with Prostate Cancer That Is Progressing on Combined Androgen Therapies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: J1416, NCI-2014-01366, CIR00006889, CIR00011018, NA_00093344, NCT02090114
Abiraterone Acetate with or without Cabazitaxel in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-046, NCI-2014-01894, c12-108, NCT02218606
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients with Hormone-Resistant Prostate Cancer
Status: Not yet active
Phase: Phase II
Type: Treatment
Age: 19 and over
Trial IDs: UCDCC#260, NCI-2016-00779, NCT02807805
Androgen Receptor Antagonist ARN-509, Abiraterone Acetate, Prednisone, Degarelix, and Indomethacin in Treating Patients with Localized Prostate Cancer Before Surgery
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9628, NCI-2016-01027, NCT02849990
Abiraterone Acetate and Androgen Receptor Antagonist ARN-509 before and after Surgery in Treating Patients with Intermediate-High Risk Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 16-223, NCI-2016-01764, NCT02903368
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CR104358, NCI-2014-02010, 2014-001426-14, 56021927PCR1010, NCT02123758
Abiraterone Acetate in Treating Patients with Hormone-Resistant Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: 11-0709, NCI-2012-00116, NCT01543776
Circulating Tumors Cells in Predicting Response to Abiraterone Acetate in Patients with Metastatic, Hormone-Resistant Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-209, NCI-2013-02355, 212082PCR2009, NCT01961843
Adaptive Abiraterone Therapy for Metastatic Castration Resistant Prostate Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: MCC-17981, NCI-2015-00648, 15.01.0005, NCT02415621
Start Over